Researchers in the laboratories of Nathanael Gray and Gerald Crabtree at Stanford University have developed and synthesized new small molecule chemotherapeutics for targeted (and potentially less toxic) treatment of cancers having high BCL6 levels including lymphomas and other
Researchers at Stanford University's Curtis Laboratory have used gene expression to categorize the sensitivity and resistance of anthracycline chemotherapy in breast cancer patients with utmost precision.
Disease indication - Cancer, specifically:
-highly mutated cancers, including the ~20% of cancer with BAF complex mutations
-combination therapy with ATR inhibitors
Disease indication - HIV infection, specifically reversal of viral latency alone or in combination with other latency reversal agents to improve reservoir targeting.
Researchers in Prof. Gerald Crabtree's laboratory have identified the pathological mechanism for synovial sarcoma (SS) that could be used to develop targeted therapeutics. This approach aims to reverse the effects of the SS18-SSX fusion protein (the hallmark of human SS).
Researchers in Prof. Gerald Crabtree's laboratory have developed a method for identifying cancer patients that are likely to benefit from treatment with topoisomerase IIa (TOP2A) inhibitors.
Researchers in Prof. Gerald Crabtree's laboratory have produced a mouse allowing high-throughput screening for activity and inhibition of virtually any chromatin modifier in any murine tissue.
NFAT-1 protein bound functional sequences of the long terminal repeat of the HIV Type 1. This LTR is known to be stimulated during early T cell activation.